CN109847067A - 一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 - Google Patents
一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 Download PDFInfo
- Publication number
- CN109847067A CN109847067A CN201811562956.5A CN201811562956A CN109847067A CN 109847067 A CN109847067 A CN 109847067A CN 201811562956 A CN201811562956 A CN 201811562956A CN 109847067 A CN109847067 A CN 109847067A
- Authority
- CN
- China
- Prior art keywords
- diclofenac
- glycine
- resveratrol
- conjugate
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940016667 resveratrol Drugs 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000004471 Glycine Substances 0.000 claims abstract description 30
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 25
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 25
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960001259 diclofenac Drugs 0.000 claims abstract description 25
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 25
- 238000010189 synthetic method Methods 0.000 claims abstract description 6
- 230000002456 anti-arthritic effect Effects 0.000 claims abstract description 4
- 239000003054 catalyst Substances 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000012024 dehydrating agents Substances 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 235000014676 Phragmites communis Nutrition 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 2
- 241000219317 Amaranthaceae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000003927 aminopyridines Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 210000001226 toe joint Anatomy 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 102000011722 Matrix Metalloproteinase 13 Human genes 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000008079 Sterol Regulatory Element Binding Protein 2 Human genes 0.000 description 1
- 108010074438 Sterol Regulatory Element Binding Protein 2 Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000489523 Veratrum Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940124347 antiarthritic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940073584 methylene chloride Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811562956.5A CN109847067B (zh) | 2018-12-20 | 2018-12-20 | 一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811562956.5A CN109847067B (zh) | 2018-12-20 | 2018-12-20 | 一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109847067A true CN109847067A (zh) | 2019-06-07 |
CN109847067B CN109847067B (zh) | 2022-06-07 |
Family
ID=66891662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811562956.5A Active CN109847067B (zh) | 2018-12-20 | 2018-12-20 | 一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109847067B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113181370A (zh) * | 2021-05-18 | 2021-07-30 | 六安市康恒生物科技有限公司 | 一种肿瘤靶向药物合成工艺 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660869A (zh) * | 2004-12-08 | 2005-08-31 | 梅县梅雁螺旋藻养殖有限公司 | 氨基葡萄糖双氯芬酸衍生物的合成方法 |
CN1800195A (zh) * | 2006-01-16 | 2006-07-12 | 中国药科大学 | 羧酸类非甾体抗炎药与氨基葡萄糖或其盐合成的化合物及其合成方法和应用 |
CN101439187A (zh) * | 2007-11-19 | 2009-05-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 新的胆汁酸-抗肝炎病毒药物偶合物及其医药用途 |
EP2422818A2 (en) * | 2010-08-27 | 2012-02-29 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Process to produce a diclofenac cyclodextrin conjugate |
CN104478890A (zh) * | 2014-11-26 | 2015-04-01 | 浙江大学 | 一种全反式维甲酸-喜树碱类抗癌药物偶联物及其制备方法和应用 |
CN104892420A (zh) * | 2015-03-27 | 2015-09-09 | 广东工业大学 | 一种白藜芦醇与羧酸类非甾体抗炎药酯化衍生物的制备方法与应用 |
-
2018
- 2018-12-20 CN CN201811562956.5A patent/CN109847067B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660869A (zh) * | 2004-12-08 | 2005-08-31 | 梅县梅雁螺旋藻养殖有限公司 | 氨基葡萄糖双氯芬酸衍生物的合成方法 |
CN1800195A (zh) * | 2006-01-16 | 2006-07-12 | 中国药科大学 | 羧酸类非甾体抗炎药与氨基葡萄糖或其盐合成的化合物及其合成方法和应用 |
CN101439187A (zh) * | 2007-11-19 | 2009-05-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 新的胆汁酸-抗肝炎病毒药物偶合物及其医药用途 |
EP2422818A2 (en) * | 2010-08-27 | 2012-02-29 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Process to produce a diclofenac cyclodextrin conjugate |
CN104478890A (zh) * | 2014-11-26 | 2015-04-01 | 浙江大学 | 一种全反式维甲酸-喜树碱类抗癌药物偶联物及其制备方法和应用 |
CN104892420A (zh) * | 2015-03-27 | 2015-09-09 | 广东工业大学 | 一种白藜芦醇与羧酸类非甾体抗炎药酯化衍生物的制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
曾戎: "《多糖基高分子药物轭合物的设计、合成、表征和评价》", 31 May 2011, 华南理工农大学出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113181370A (zh) * | 2021-05-18 | 2021-07-30 | 六安市康恒生物科技有限公司 | 一种肿瘤靶向药物合成工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN109847067B (zh) | 2022-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI92388C (fi) | Menetelmä karbasykliinianalogien terapeuttisesti käyttökelpoisten syklodekstriiniklatraattien valmistamiseksi | |
CN105251013B (zh) | 一种具有氧化还原响应性可降解水溶性抗肿瘤聚合物前药及其制备方法 | |
AU2005220192A1 (en) | Aryl boronic acids for treating obesity | |
CN102671189A (zh) | 一种蛋白琥珀酸铁增溶方法及其口服溶液制剂 | |
CN101732728B (zh) | 抗炎药物-多糖偶联物及其药物组合物的制备和应用 | |
CN107686506B (zh) | 华法林-4-o-乙酰-gprp,其合成,活性和应用 | |
DE2433407A1 (de) | Sulfate von hydroxyaethylstaerke | |
CN109847067A (zh) | 一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 | |
CN100460413C (zh) | 羧酸类非甾体抗炎药与氨基葡萄糖或其盐合成的化合物及其合成方法和应用 | |
CN111349108A (zh) | 一种阿司匹林类衍生物及其制备方法、药物、应用 | |
Chalmers | Studies on the mechanism of formation of 5-mercapto-1-methyl-4-nitroimidazole, a metabolite of the immunosuppressive drug azathioprine | |
WO2021190495A1 (zh) | 负载羧酸抗肿瘤药物的peg化肝素纳米胶束及其制备方法 | |
AU2019243422A1 (en) | Pharmaceutical compositions containing polyrotaxanes | |
CN101703588A (zh) | 双黄连原位凝胶制剂及其制备方法 | |
KR20010082721A (ko) | 지방산 함유 조성물 | |
CN110812489B (zh) | 治疗急性肾损伤的双级靶向高分子前体药物及制备方法 | |
EP0249779B1 (en) | Methylated chitosans and their use for the preparation of pharmaceutical compositions | |
CN106631957A (zh) | 一种靶向FAP‑alpha酶的抗肿瘤化合物及其制备方法与应用 | |
CN103641889A (zh) | 一种降糖肽及其药物用途 | |
CN104017032B (zh) | 鞣酸刺乌头碱及其制备方法与用途 | |
CN102212148B (zh) | 一种静脉注射用抗血栓药及其制备方法和应用 | |
CN102351888B (zh) | 一种芒果苷元药用配合物及其制备方法与应用 | |
CN113559275A (zh) | 一种一锅法制备高分子/康普瑞汀a4/blz945纳米键合药的方法 | |
US20090239822A1 (en) | Process for the preparation of esters of diacerein with hyaluronic acid and pharmaceutical compositions containing such esters | |
CN108484709B (zh) | 灯盏花乙素镁化合物、其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A diclofenac glycine resveratrol coupling compound, preparation method and application Effective date of registration: 20230105 Granted publication date: 20220607 Pledgee: Zijin Trust Co.,Ltd. Pledgor: CPU-PHARMA Co.,Ltd. Registration number: Y2022980029390 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20220607 Pledgee: Zijin Trust Co.,Ltd. Pledgor: CPU-PHARMA Co.,Ltd. Registration number: Y2022980029390 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Diclofenac Glycine Resveratrol Coupling Compound, Preparation Method and Application Granted publication date: 20220607 Pledgee: Jiangsu Zijin Rural Commercial Bank Co.,Ltd. Gulou sub branch Pledgor: CPU-PHARMA Co.,Ltd. Registration number: Y2024980008966 |